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Reduction in Recurrent Cardiovascular Events
With Intensive Lipid-Lowering Statin Therapy
Compared With Moderate Lipid-Lowering Statin
Therapy After Acute Coronary Syndromes
From the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In Myocardial
Infarction 22) Trial
Sabina A. Murphy, MPH, Christopher P. Cannon, MD, Stephen D. Wiviott, MD,
Carolyn H. McCabe, BS, Eugene Braunwald, MD
Boston, Massachusetts
Objectives In addition to reducing first events in patients after an acute coronary syndrome (ACS), we hypothesized that
high-dose atorvastatin 80 mg would also reduce recurrent cardiovascular events, and therefore total events,
compared with pravastatin 40 mg during the 2-year follow-up.
Background In the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocar-
dial Infarction 22) trial, more intensive lipid lowering with high-dose atorvastatin reduced the first occurrence of
the primary end point (death, myocardial infarction, unstable angina requiring rehospitalization, stroke, or revas-
cularization 30 days) compared with moderate lipid lowering with pravastatin.
Methods Poisson regression analysis was performed to compare the number of occurrences of the primary end point be-
tween high-dose atorvastatin and pravastatin in the PROVE IT–TIMI 22 trial.
Results As previously reported, first primary end point events were reduced by 16% with atorvastatin 80 mg versus prav-
astatin 40 mg (n  464 vs. n  537, respectively; p  0.005). Additional events were also reduced by 19% with
atorvastatin 80 mg (n  275 vs. n  340, respectively; p  0.009). Overall, there were 138 fewer primary effi-
cacy events with atorvastatin 80 mg versus pravastatin 40 mg (n  739 vs. n  877, respectively; rate ratio:
0.85, 95% confidence interval: 0.77 to 0.94, p  0.001).
Conclusions Although analytic techniques commonly used in clinical outcomes trials censor patients who experience a component
of the primary composite end point, total cardiovascular events are important to patients, clinicians, and health care
payers. Maintaining low levels of low-density lipoprotein cholesterol is central to preventing additional atherosclerotic
development and subsequent cardiovascular events. Atorvastatin 80 mg, a more intensive low-density lipoprotein
cholesterol lowering agent, reduced both first and subsequent primary end point events compared with pravastatin
40 mg after ACS. (J Am Coll Cardiol 2009;54:2358–62) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005f
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December 15/22, 2009:2358–62 Recurrent Events and Lipid-Lowering Therapy in ACSndividual events, particularly if a treatment reduces the
ncidence of 1 type of event and increases the incidence of
nother (1). Additionally, if the events have a different
mpact on either quality of life or health care costs, it may be
mportant to examine the frequency and treatment effects of
he different events (1). Although data on all events occur-
ing during the study are often collected, reporting of such
vents is generally examined by individual end points rather
han by total number of cardiovascular events that occurred.
rom a clinical perspective, patients and physicians are
oncerned not only with the initial event a patient may
xperience but also with subsequent events. We recently
xamined the impact of more potent antiplatelet therapy on
otal cardiovascular events (2), but the impact of more
ntensive lipid-lowering therapy on total cardiovascular
vents has not been explored.
Compared with moderate lipid lowering using standard-
ose pravastatin therapy, intensive lipid lowering with high-
ose atorvastatin therapy after acute coronary syndrome
ACS) significantly reduced the first occurrence of the
rimary end point of death, myocardial infarction (MI),
troke, unstable angina (UA) requiring rehospitalization, or
evascularization occurring 30 days after the index ACS
aseline Characteristics of Patients With No Events, a Single EvenTable 1 Baseline Characteristics of Patients With No Events, a
No Events
(n  3,161)
Age, yrs 57 (50–65)
Age 65 yrs 27.9%
Male 77.8%
White race 90.5%
History of diabetes mellitus 15.8%
History of hypertension 47.3%
History of hypercholesterolemia 48.8%
Prior MI 16.3%
Prior PCI 13.7%
Prior CABG 9.4%
History of heart failure 2.7%
History of peripheral vascular disease 4.6%
History of renal disease 8.1%
History of stroke 4.9%
TIMI risk score
0–2 45.4%
3–4 49.2%
5–6 5.4%
Current smoker 37.5%
Index event
ST-segment elevation MI 35.0%
Non–ST-segment elevation MI 37.4%
Unstable angina 27.5%
Statin use in the 2 weeks before qualifying event 23.7%
Randomized to atorvastatin 51.7%
Total cholesterol at baseline, mg/dl 180 (160–204
Low-density lipoprotein cholesterol at baseline, mg/dl 106 (89–127)
Triglycerides at baseline, mg/dl 156 (118–210
C-reactive protein at baseline, mg/l 12.0 (4.9–28.3alues are median (interquartile range) or %.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction; PCI  percutaneous coronavent in the PROVE IT–TIMI
2 (Pravastatin or Atorvastatin
valuation and Infection Thera-
y–Thrombolysis In Myocardial
nfarction 22) trial (3,4). We hy-
othesized that atorvastatin 80
g would also reduce recurrent
ardiovascular events and there-
ore total events compared with
ravastatin 40 mg during the
-year follow-up.
ethods
he study design and primary results papers for
he PROVE IT–TIMI 22 trial have been published previ-
usly (3,5). The trial enrolled 4,162 patients with an ACS
ithin the prior 10 days. Patients were ran-
omly assigned to either 80 mg atorvastatin (intensive lipid
owering) or 40 mg pravastatin (moderate lipid lowering).
rior statin use was not an exclusion criterion in the
ROVE IT–TIMI 22 trial. Baseline and on-treatment lipid
evels and high-sensitivity C-reactive protein (CRP) were
Multiple Eventsle Event, or Multiple Events
Single Event
(n  621)
Multiple Events
(n  380) p Value
60 (53–69) 59 (50–67) 0.001
36.1% 32.6% 0.001
81.0% 76.1% 0.125
91.3% 91.8% 0.618
20.3% 28.7% 0.001
53.5% 57.5% 0.001
52.5% 58.4% 0.001
24.2% 27.1% 0.001
19.5% 23.2% 0.001
13.8% 18.4% 0.001
4.4% 6.6% 0.001
7.9% 12.1% 0.001
10.6% 14.1% 0.001
6.0% 8.4% 0.013
0.001
36.7% 36.3%
57.2% 52.9%
6.1% 10.8%
32.5% 37.1% 0.061
0.001
35.0% 30.0%
32.4% 31.6%
32.6% 38.4%
28.8% 31.6% 0.001
46.2% 46.6% 0.012
180 (157–201) 183 (160–206) 0.320
105 (85–126) 106 (85–127) 0.465
151 (114–212) 162 (124–220) 0.044
13.8 (5.4–34.3) 11.2 (4.5–29.4) 0.051
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CRP  C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
UA  unstable anginat, orSing
)
)
)ry intervention; TIMI  Thrombolysis In Myocardial Infarction.
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or clinical events for an average of 2 years.
All end points used in the analyses were adjudicated by
embers of an independent clinical events committee who
ere blinded to the treatment assignment (5). Fatal events
ere counted as a single event, not as 2 separate events. For
xample, if a patient experienced an MI and then had
ardiovascular death with the cause of death adjudicated as
eing due to the MI, the event was considered 1 fatal MI
vent and was both an MI and cardiovascular death.
atients were to remain on the study drug even if the subject
xperienced 1 of the nonfatal efficacy end points of the study.
The present analysis was not pre-specified in the primary
nalytic plan and should be considered exploratory. Baseline
linical characteristics are presented as frequencies for categor-
cal variables and as medians and interquartile ranges for
ontinuous variables. Comparisons between baseline character-
stics for patients with no events, a single event, or multiple
vents were made using the chi-square test for categorical variables
nd Kruskal-Wallis for continuous variables. Poisson regression
nalysis was performed to compare the total number of occur-
ences of the primary end point between all patients in the
torvastatin and pravastatin groups. Analyses were performed
sing Stata/SE version 9.2 (Stata Corp., College Station, Texas).
esults
atients who had multiple events had more frequent comor-
idities at study entry, including a history of diabetes mellitus,
ypertension, and hypercholesterolemia (Table 1). Interest-
ngly, patients who had multiple events were more likely to
resent with UA as the index event. There was no difference in
aseline low-density lipoprotein cholesterol (LDL-C) or total
holesterol among patients who had multiple events compared
ith patients who had no event or a single event, but
riglycerides were higher among patients who had multiple
vents. Patients having multiple events were more likely to
ave been statin users before the qualifying event (31.6% for
atients with multiple events, 28.8% for patients with single
vent, 23.7% for patients with no events; p  0.001).
The primary end point of first occurrence of death, MI,
troke, UA requiring rehospitalization, or revascularization
ccurring30 days after the index ACS event was significantly
educed among patients randomly assigned to intensive lipid-
owering therapy with atorvastatin 80 mg as compared with
oderate lipid-lowering therapy with pravastatin 40 mg
22.4% [n 464] vs. 26.3% [n 537], hazard ratio: 0.84, 95%
onfidence interval: 0.74 to 0.95, p  0.005), as previously
eported (3). Thus, by the usual analysis that takes account of
nly first events, the difference between the 2 treatment arms
as 73 events. In addition to the reduction in first events,
ubsequent events were also reduced in the atorvastatin 80 mg
roup (n  275 in the atorvastatin 80 mg group vs. n  340
n the pravastatin 40 mg group, p  0.009) (Fig. 1), resulting
n 138 fewer total primary events during follow-up (total events
 739 vs. n 877, rate ratio: 0.85, 95% confidence interval: c.77 to 0.94, p  0.001). Using a marginal Cox proportional
azards model rather than a Poisson regression analysis pro-
uced a hazard ratio of 0.82 (p  0.008) in favor of the
torvastatin 80 mg group. Among the additional events, there
ere 177 second events in the atorvastatin 80 mg group (8 fatal
nd 169 nonfatal) versus 203 second events in the pravastatin
0 mg group (12 fatal and 191 nonfatal), and 60 third events
n the atorvastatin 80 mg group (3 fatal and 57 nonfatal) versus
4 third events in the pravastatin 40 mg group (3 fatal and 71
onfatal).
When examining the individual components of the pri-
ary composite end point, the majority of additional events
educed in the atorvastatin 80 mg group were UA events
equiring rehospitalization and revascularization, with a
imilar number of deaths, MI, and strokes (Table 2).
Among patients with a single event or multiple events,
holesterol and CRP levels before the event were compared
o those of the final study sample for patients with no events
Table 3). Total cholesterol, LDL-C, and high-density
ipoprotein cholesterol were lower and CRP was higher
mong patients with single and recurrent end point events
han among patients without any end point events.
The overall rate of permanent study drug discontinuation
ithin 30 days after the first event was low (3.0%) and did
ot differ by randomized group (3.3% in the atorvastatin 80
g group vs. 2.7% in the pravastatin 40 mg group, p 
.56). There were no cases of recurrent myalgia or myositis
n the trial in either treatment group. Among patients with
o events, compliance was classified as good in 85% of
atients at the last contact with available compliance data.
mong patients with 1 event, compliance was classified as
ood in 91% of patients at the contact before the event,
hereas 88% of patients with 1 event had compliance
Figure 1 Total Primary End Point
Events by Randomized Therapy
The atorvastatin 80 mg group had a lower number of first events,
additional events, and total events as compared with the pravastatin 40 mg group.
Bright blue (top, left)  additional events, pravastatin 40 mg; lighter blue (bot-
tom, left)  first events, pravastatin 40 mg; orange (top, right)  additional
events, atorvastatin 80 mg; and yellow (bottom, right)  first events, atorvastatin
80 mg.lassified as good.
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his analysis from the PROVE IT–TIMI 22 trial demon-
trates that intensive lipid-lowering therapy with high-dose
torvastatin therapy after an ACS prevented not only the first
ccurrence of the primary end point of death, MI, stroke, UA
equiring rehospitalization, or revascularization but also re-
uced subsequent, and thus the total number of, primary end
oint events among patients with an ACS. These findings
uggest that continued therapy with a regimen that maintains
ow LDL-C is central to preventing additional atherosclerotic
evelopment and cardiovascular events, including recurrent
vents. Based on the primary end point results from the
ROVE IT–TIMI 22 trial, the number of patients needed to
reat to prevent the first occurrence of the primary end point is
6. However, when considering total events, the needed-to-
reat number to prevent 1 event is much lower, at 14.
Several studies have shown that when compared with
lacebo, the risk of death and cardiovascular events is lowered
y reducing LDL-C levels with statin therapy for both primary
nd secondary prevention (6). More recent trials, such as the
ROVE IT–TIMI 22 study and the TNT (Treating to New
argets) trial, demonstrated that further reductions in LDL-C
evels with more intensive statin therapy conferred additional
linical benefit (3,7,8). The JUPITER (Justification for the Use
f Statins in Primary Prevention: an Intervention Trial Eval-
ating Rosuvastatin) trial extended these findings, demonstrat-
ng improved outcomes for patients with lipid levels considered
ptimal under current guidelines but with elevated levels of
igh-sensitivity CRP (9,10). While these studies have shown
rimary End Point Events by Randomized TherapyTable 2 Primary End Point Events by Randomized Therapy
Initial Events
Pravastatin
40 mg
Atorvastatin
80 mg
Pravasta
40 mg
Any 537 464 340
Death* 49 32 18
MI 121 103 64
Stroke 14 17 7
UA requiring rehospitalization 77 66 46
Revascularization 30 days
after index ACS event
276 246 205
To avoid double counting, fatal cardiovascular events were counted as a single event, not as 2 s
ACS  acute coronary syndrome; MI  myocardial infarction; UA  unstable angina.
Cholesterol and CRP Among PatientsWith No Events, a Single Event, or Multiple EveTable 3 Cholestero a d CRP Among PatienWith No Events, a Single Event, or
No Events
(n  3,002)
Total cholesterol, mg/dl 160 (134–189)
LDL-C, mg/dl 85 (65–109)
HDL-C, mg/dl 42 (35–50)
CRP, mg/l 1.7 (0.8–3.8)
Values are median (interquartile range). *Final sample used for patien
C-reactive protein (CRP) measured only at 30 days, 4 months, and final sam
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotemproved outcomes with statin therapy to lower LDL-C
evels, the primary end point for each trial was time to
ccurrence of a first major cardiovascular event, the exact
efinitions of which varied, but all of which were composite
nd points. The reduction in first event has been consistent
cross the studies, but total number of events prevented has not
een fully reported.
Unexpectedly, the median LDL-C measured before the first
vent for patients having an event and measured at study end
or patients without an event was lower in patients with single
nd recurrent end point events than in patients without any
nd point events. While the exact cause of this finding is not
nown, it is likely confounded by the observation that patients
ith single or multiple events more frequently presented as
tatin users before the qualifying event, contributing to the
ower LDL-C; thus, the lower LDL-C levels in patients with
vents may be a spurious finding. It is also possible that the
ifference may be due to the timing of the LDL-C measure-
ents, which were taken at a median of 2 years, at the time of
he final study visit of patients without an event, and at a median
f 6 months for patients with an event. Compliance with study
rug medication is likely greatest early in the trial when the
DL-C measurement was used for the cohort with a single or
ultiple event and lower at trial end when the LDL-C measure-
ent was used for the cohort without any events.
Expanded analysis of total events during the course of
herapy may warrant more consideration in future trials,
iven the attention focused on health care resource utiliza-
ion. Despite the frequent practice of censoring patients
ditional Events Total Events
Atorvastatin
80 mg p Value
Pravastatin
40 mg
Atorvastatin
80 mg p Value
275 0.009 877 739 0.001
15 0.568 67 47 0.053
57 0.472 185 160 0.218
8 0.821 21 25 0.529
18 0.001 123 84 0.009
177 0.127 481 423 0.081
events.
ple Events*
gle Event
 528)
Multiple Events
(n  317) p Value
(127–184) 156 (127–188) 0.001
(58–106) 83 (61–105) 0.001
(35–48) 40 (34–48) 0.029
(0.8–4.6) 2.2 (1.0–4.4) 0.005
no events; sample preceding first event used for patients with events;Ad
tinnts*ts
Multi
Sin
(n
153
79
41
1.9
ts with
ple.
in cholesterol.
w
p
d
a
t
r
c
t
l
e
f
t
a
d
t
t
e
a
h
p
t
w
p
e
e
h
l
t
p
e
t
3
O
I
t
r
e
c
t
l
e
s
u
r
p
i
o
h
m
a
m
i
f
c
w
p
R
n
B
R
1
1
1
1
1
1
1
2362 Murphy et al. JACC Vol. 54, No. 25, 2009
Recurrent Events and Lipid-Lowering Therapy in ACS December 15/22, 2009:2358–62ho experience a component of the primary composite end
oint in standard statistical analysis of clinical outcomes trial
ata, all events occurring during the course of the entire trial
re important to patients, clinicians, and payers (11). Mul-
iple ischemic events result in higher mortality and a
educed quality of life (12). Multiple events can also increase
osts by requiring more hospitalizations, diagnostic tests,
reatments, and physician visits. Another method for ana-
yzing multiple events is to perform a landmark analysis to
xplore the treatment effect beyond a pre-determined time-
rame to evaluate for both early and late benefit. While this
ype of analysis can be informative, it should be interpreted
s a post-randomization analysis because there may be
ifferences among patients who were censored because of
he occurrence of a fatal event or differences in concomitant
reatments among patients who experienced a nonfatal
vent during the early part of the trial. Other methods for
nalyzing multiple events in the presence of a terminal event
ave also been described by Chen and Cook (1), who
ropose use of marginal cumulative mean functions between
reatment groups and reporting of a global test statistic.
Although cost-effectiveness analyses incorporate total costs
hen available, including repeat hospitalizations and multiple
rocedures, multiple events are often not incorporated into the
ffectiveness component of the analysis (13). From a cost
conomics perspective, the occurrence of multiple events would
ave a negative impact on long-term outcomes of both
ife-years and quality-adjusted life-years. Incorporating the
otal number of events into cost-effectiveness analyses may
rovide a more comprehensive estimate of the total cost
ffectiveness of a given therapy when the agent has been shown
o reduce events beyond the first occurrence of the end point.
In a similar analysis of total events in the TRITON–TIMI
8 (Trial to Assess Improvement in Therapeutic Outcome by
ptimizing Platelet Inhibition With Prasugrel–Thrombolysis
n Myocardial Infarction 38) study, more potent antiplatelet
herapy with the novel thienopyridine prasugrel was shown to
educe first, subsequent, and total occurrences of the primary
nd point of cardiovascular death, MI, or stroke compared with
lopidogrel (2). As with the current analysis, which suggests
hat continued therapy with a more intensive lipid-
owering agent confers added benefit beyond the first
vent, the TRITON–TIMI 38 study analysis demon-
trated the need for maintaining treatment with contin-
ed high levels of platelet inhibition after an ACS.
The National Cholesterol Education Program currently
ecommends an optional target LDL-C of 70 mg/dl for
atients at high risk of cardiovascular events (14–16),
ncluding those with an ACS event. Baseline characteristics
f patients in the present study were analyzed to identify
igh-risk characteristics associated with the occurrence of
ultiple events. Although baseline LDL-C levels did not differ
mong patients without an event, with a single event, or with
ultiple events, baseline triglyceride levels were slightly higher
n patients who had multiple events. Other established risk
actors such as diabetes mellitus and hypertension were most
K
common among patients having multiple events. Presentation
ith an index event of UA was also more frequent among
atients who experienced multiple events.
eprint requests and correspondence: Dr. Christopher P. Can-
on, TIMI Study Group, 350 Longwood Avenue, First Floor,
oston Massachusetts 02115. E-mail: cpcannon@partners.org.
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